The present invention relates to a method for determining whether a patient is likely to benefit from treatment with a therapeutic formulation, the method comprising the steps of: (a) determining the concentration of corticotropin releasing hormone (CRH) in a sample from a patient prior to administration of the therapeutic formulation； (b) determining the concentration of CRH in a sample from a patient subsequent to administration of the therapeutic formulation； and (c) comparing the concentration of CRH pre-administration with the concentration of CRH subsequent to administration； wherein an increase in patient CRH concentration subsequent to administration indicates that the patient is likely to benefit from treatment with the therapeutic formulation and wherein no increase or a decrease in patient CRH concentration subsequent to administration indicates that the patient is unlikely to benefit from treatment with the therapeutic formulation. The patient may have multiple sclerosis or systemic sclerosis. The therapeutic formulation may be derived from an ungulate such as a goat and may contain CRH, CRH-binding protein, pro-opiomelanocortin (POMC) and alpha-2 macroglobulin. Also provided are methods of treating a patient with a disorder such as multiple sclerosis or systemic sclerosis.La présente invention concerne un procédé permettant de déterminer si un patient est susceptible de tirer bénéfice d'un traitement comprenant une formulation thérapeutique, le procédé consistant : (a) à déterminer la concentration d'hormone de libération de la corticotropine (CRH) dans un échantillon provenant d'un patient avant l'administration de la formulation thérapeutique ； (b) à déterminer la concentration de CRH dans un échantillon provenant d'un patient après l'administration de la formulation thérapeutique ； et (c) à comparer la concentration avant l'administration de CRH avec la concentration de CRH après l'administration ； une augmentation de la concentration de CRH chez le
